Clovis Oncology (CLVS) Position Raised by Swiss National Bank
Swiss National Bank lifted its holdings in shares of Clovis Oncology (NASDAQ:CLVS) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,050 shares of the biopharmaceutical company’s stock after buying an additional 3,400 shares during the period. Swiss National Bank owned approximately 0.17% of Clovis Oncology worth $2,557,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Macquarie Group Ltd. boosted its position in shares of Clovis Oncology by 12.3% during the second quarter. Macquarie Group Ltd. now owns 691,459 shares of the biopharmaceutical company’s stock valued at $31,441,000 after buying an additional 75,589 shares during the last quarter. Creative Planning boosted its position in Clovis Oncology by 11.4% in the third quarter. Creative Planning now owns 88,177 shares of the biopharmaceutical company’s stock worth $2,590,000 after purchasing an additional 9,000 shares during the last quarter. Northern Trust Corp boosted its position in Clovis Oncology by 9.5% in the second quarter. Northern Trust Corp now owns 611,459 shares of the biopharmaceutical company’s stock worth $27,803,000 after purchasing an additional 53,266 shares during the last quarter. Morse Asset Management Inc boosted its position in Clovis Oncology by 14.0% in the second quarter. Morse Asset Management Inc now owns 13,400 shares of the biopharmaceutical company’s stock worth $609,000 after purchasing an additional 1,650 shares during the last quarter. Finally, Highland Capital Management LP boosted its position in Clovis Oncology by 39.4% in the second quarter. Highland Capital Management LP now owns 24,400 shares of the biopharmaceutical company’s stock worth $1,109,000 after purchasing an additional 6,900 shares during the last quarter.
NASDAQ CLVS opened at $19.99 on Wednesday. The company has a debt-to-equity ratio of 2.46, a quick ratio of 8.46 and a current ratio of 9.03. Clovis Oncology has a 52 week low of $11.50 and a 52 week high of $69.02. The stock has a market capitalization of $907.17 million, a PE ratio of -3.90 and a beta of 2.12.
CLVS has been the topic of several research reports. Piper Jaffray Companies reissued a “neutral” rating on shares of Clovis Oncology in a research report on Friday, October 19th. Cann reissued a “hold” rating on shares of Clovis Oncology in a research report on Friday, October 19th. JPMorgan Chase & Co. cut Clovis Oncology from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $71.00 to $16.00 in a research report on Wednesday, October 31st. Leerink Swann raised Clovis Oncology from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Finally, Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, October 30th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company’s stock. Clovis Oncology currently has a consensus rating of “Hold” and an average price target of $56.32.
COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/clovis-oncology-clvs-position-raised-by-swiss-national-bank/2662715.html.
Clovis Oncology Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Featured Article: Federal Reserve
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.